MBX Biosciences, Inc. Common Stock

NASDAQ:MBX

Biotechnology

Healthcare
$53.42 -1.54%

-$0.64 today

Market cap
$2.65B
Beta
0.75
P/E (TTM)
-22.0
EPS (TTM)
-$1.86
52W Low $9.43High $45.85

Volume 0.73M

Average 0.65M

MBX EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

MBX Biosciences, Inc. Common StockNASDAQ: MBX

EBITDA · Q3 FY2026 · quarter ended Sep 2026

EBITDA remains negative

Q3 FY2026 EBITDA was -$62.28M, compared with -$21.57M a year earlier. Trailing-twelve-month EBITDA was -$148.59M.

Context

  • EBITDA grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -40.6% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
-$62.28M-52.5% QoQ
Last fiscal yearDec 2025
-$86.72M-40.6% YoY
LTMSep 2026
-$148.59M-85.2% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-188.8%+100.0%+288.8 pp
1 year-40.6%+100.0%+140.6 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(86.72M) USD
Year-over-year change
-40.6%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How MBX compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -85.2% is the 7th highest of 8, against a peer median of +63.6%.
MBX Competitors
EBITDA for MBX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ASNDAscendis Pharma A/SLTM Sep 2026€259.93M EUR+295.2%—21.5%
ORMPOramed Pharmaceuticals Inc.LTM Mar 2026$78.84M USD+1391.3%——
XERSXeris Biopharma Holdings, Inc.LTM Mar 2026$46.13M USD+1163.1%—14.7%
BMEABiomea Fusion, Inc.LTM Mar 2026-$46.12M USD+63.6%——
ALTAltimmune, Inc.LTM Mar 2026-$88.27M USD+2.7%—245200.0%
MBXMBX Biosciences, Inc. Common StockLTM Sep 2026-$148.59M USD-85.2%——
KLRAKailera Therapeutics, Inc.FY2025-$158.03M USD———
RYTMRhythm Pharmaceuticals, Inc.LTM Sep 2026-$173.24M USD-2.5%—61.7%
VKTXViking Therapeutics, Inc.LTM Jun 2026-$534.34M USD-212.4%——
Peer median (excluding MBX) —+63.6%—41.6%

Competitors are the stored peer set for MBX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0000
Cost of Revenue000248K
Gross Profit000(248K)
Gross Margin————
Research & Development21.4M28.53M57.42M79.16M
Selling, General & Admin3.76M6.78M10.78M18.9M
Operating Expenses25.16M35.31M68.19M98.06M
Depreciation & Amortization56K157K244K248K
EBITDA(25.71M)(32.41M)(61.68M)(86.72M)
EBITDA Margin————
Operating Income(25.16M)(35.31M)(68.19M)(98.06M)
Operating Margin————
Interest Income372K2.75M6.27M11.08M
Interest Expense374K000
Other Income / Expenses(974K)2.75M6.27M11.08M
Income Before Tax(26.14M)(32.56M)(61.92M)(86.97M)
Pre-Tax Margin————
Income Tax Expense0000
Net Income(26.14M)(32.56M)(61.92M)(86.97M)
Net Margin————
EPS (Basic)(0.82)(1.02)(1.85)(2.38)
EPS (Diluted)(0.82)(1.02)(1.85)(2.38)
Weighted Avg Shares31.85M31.85M33.39M36.51M
Weighted Avg Shares (Diluted)31.85M31.85M33.39M36.51M

MBX Biosciences, Inc. Common Stock

NASDAQ:MBX

Intrinsic Alpha fair value

Locked

Current Price

$53.42

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.